304 related articles for article (PubMed ID: 19957540)
1. Studies on formulation development of mouth dissolving tablets of Carvedilol.
Pokharkar V; Dhar S; Mandpe L
Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):21-8. PubMed ID: 19957540
[TBL] [Abstract][Full Text] [Related]
2. Ternary complexation of carvedilol, beta-cyclodextrin and citric acid for mouth-dissolving tablet formulation.
Pokharkar V; Khanna A; Venkatpurwar V; Dhar S; Mandpe L
Acta Pharm; 2009 Jun; 59(2):121-32. PubMed ID: 19564138
[TBL] [Abstract][Full Text] [Related]
3. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system.
Cappello B; De Rosa G; Giannini L; La Rotonda MI; Mensitieri G; Miro A; Quaglia F; Russo R
Int J Pharm; 2006 Aug; 319(1-2):63-70. PubMed ID: 16650700
[TBL] [Abstract][Full Text] [Related]
4. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate.
Srikanth Meka V; Wee Liang VA; Dharmalingham SR; Sheshala R; Gorajana A
Acta Pharm; 2014 Dec; 64(4):485-94. PubMed ID: 25531788
[TBL] [Abstract][Full Text] [Related]
5. Formulation development of carvedilol compression coated tablet.
Shah R; Patel S; Patel H; Pandey S; Shah S; Shah D
Pharm Dev Technol; 2013; 18(4):906-15. PubMed ID: 21797662
[TBL] [Abstract][Full Text] [Related]
6. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
Aljimaee YH; El-Helw AR; Ahmed OA; El-Say KM
Drug Des Devel Ther; 2015; 9():1379-92. PubMed ID: 25834396
[TBL] [Abstract][Full Text] [Related]
7. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
Szabó P; Sebe I; Stiedl B; Kállai-Szabó B; Zelkó R
J Pharm Biomed Anal; 2015 Nov; 115():359-67. PubMed ID: 26280924
[TBL] [Abstract][Full Text] [Related]
8. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
Yedurkar P; Dhiman MK; Petkar K; Sawant K
J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
[TBL] [Abstract][Full Text] [Related]
9. Systematic development of pH-independent controlled release tablets of carvedilol using central composite design and artificial neural networks.
Aktas E; Eroglu H; Kockan U; Oner L
Drug Dev Ind Pharm; 2013 Aug; 39(8):1207-16. PubMed ID: 22804226
[TBL] [Abstract][Full Text] [Related]
10. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
Thimmasetty J; Pandey G; Babu P
Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
[TBL] [Abstract][Full Text] [Related]
11. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol.
Wei L; Li J; Guo L; Nie S; Pan W; Sun P; Liu H
Drug Dev Ind Pharm; 2007 Sep; 33(9):990-8. PubMed ID: 17891586
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid.
Yuvaraja K; Khanam J
J Pharm Biomed Anal; 2014 Aug; 96():10-20. PubMed ID: 24705456
[TBL] [Abstract][Full Text] [Related]
13. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
Singh B; Singh R; Bandyopadhyay S; Kapil R; Garg B
Colloids Surf B Biointerfaces; 2013 Jan; 101():465-74. PubMed ID: 23010056
[TBL] [Abstract][Full Text] [Related]
14. Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
Patel NV; Chotai NP; Patel MP
Pharmazie; 2008 Apr; 63(4):275-81. PubMed ID: 18468386
[TBL] [Abstract][Full Text] [Related]
15. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
Singh B; Khurana L; Bandyopadhyay S; Kapil R; Katare OO
Drug Deliv; 2011 Nov; 18(8):599-612. PubMed ID: 22008038
[TBL] [Abstract][Full Text] [Related]
16. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
17. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
Sica DA
Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
[No Abstract] [Full Text] [Related]
18. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes.
Cirri M; Rangoni C; Maestrelli F; Corti G; Mura P
Drug Dev Ind Pharm; 2005 Aug; 31(7):697-707. PubMed ID: 16207617
[TBL] [Abstract][Full Text] [Related]
19. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol.
Zhang Y; Zhi Z; Li X; Gao J; Song Y
Int J Pharm; 2013 Sep; 454(1):403-11. PubMed ID: 23850816
[TBL] [Abstract][Full Text] [Related]
20. Development of orally disintegrating tablets of Perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex.
Wang L; Zeng F; Zong L
Pharm Dev Technol; 2013; 18(5):1101-10. PubMed ID: 22759202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
